• News

"Mount Sinai Researchers Use Multi-Omics Approach To Personalize Relapsed Multiple Myeloma Treatment" - John Gilmore

  • Genome Web
  • New York, NY
  • (August 13, 2018)

Mount Sinai researchers have developed a DNA- and RNA-based sequencing computational method to identify genetic mutations in patients with relapsed multiple myeloma and potentially tailor treatments based on tumor susceptibility to certain drugs. "The drugs we can look at using DNA mutations are a smaller set than we could potentially observe for RNA,” explained Samir Parekh, MBBS, associate professor of oncological sciences, medicine, hematology and medical oncology and director of translational research in myeloma at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “Multiple myeloma is not as easily segmented into actionable items for treatment like other conditions such as lung cancer, forcing us to come up with a new strategy.” In the study, Dr. Parekh and his team performed a precision medicine trial of their approach using a group of 64 relapsed multiple myeloma patients. "We are treating not just monolithic cases, but different clones of the disease, where each might have different sensitivity to chemotherapy," Dr. Parekh said. "We therefore need to actively plan a combination approach that would target each clone."

- Samir Parekh, MBBS, Associate Professor, Oncological Sciences, Medicine, Hematology and Medical Oncology, Director, Translational Research in Myeloma, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Learn more